Beauty brand partners with longevity companies a

Gordian Bio CEO explains how a cutting-edge in v

Study aims to determine whether MKK4 inhibitor c

Led by figures from Oxford, Genomics England and

Companies join forces to discover and develop ne

Company’s latest product continuously monitors

Neurotech firm Somnee secures funding to scale p

Shift Bioscience identifies potent, pluripotency

New consumer longevity brand to support company’s clinical development of therapeutics based on proprietary resveratrol delivery platform. Clinical stage biotech Jupiter Neurosciences has officially launched a new line of consumer supplements designed to support health and performance, broadening its focus from clinical-stage pharmaceuticals into the consumer longevity market. The company is leveraging its proprietary micellar resveratrol delivery technology to the nutraceutical space, offering a range of supplements designed to enhance healthspan, cognitive clarity and metabolic resilience. The new supplement brand, called Nugevia, emerges from Jupiter’s primary focus on optimizing the therapeutic delivery of resveratrol to target neuroinflammation and combat neurodegenerative diseases. Resveratrol, a compound long recognized for its potential antiaging and anti-inflammatory effects, has been limited in its clinical utility due to poor bioavailability and adverse gastrointestinal effects at higher doses. Jupiter claims its proprietary platform, JOTROL, addresses these limitations through a micellar formulation that improves absorption while maintaining a strong safety profile. In clinical studies, the company says JOTROL demonstrated a ninefold increase in bioavailability without the gastrointestinal side effects typically associated with high-dose resveratrol. “The launch of Nugevia is the natural next step in translating our science into broad, real-world impact,” said Jupiter CEO Christer Rosén. “By building…

NFX General Partner Omri Drory wonders why more

Preclinical data suggest Telomir’s oral drug m

RLS-1496 enters Phase 1 aiming to modulate GPX4

Acquisition expected to support strategic collab

Genomics co-founder explains why recent advances

From state legislation to Capitol Hill coalition

Sleep is important to our physical and mental heal

Study finds AI-discovered and designed drug deli

New epigenetic clock measures intrinsic capacity

Longevity Docs’ David Luu on building a global

WormGazer platform automates the study of thousa

Digital health company leverages ‘behavior cha

Company targets obesity after IND-enabling studi

Company targets huge failure rate in clinical tr

Network’s investment strategy focuses on compa

Phil Newman joins GWI’s podcast to discuss how

Consumer longevity company partners with wellnes

Biohacker, entrepreneur and Blueprint creator wi

Elon Musk’s neurotech company valued at $9 bil

Circulate Health and Buck researchers find that

Salk study finds ERRs as vital to mitochondrial

Clinical stage biotech gears up for industry fir

VITAL sub-study shows vitamin D may help preserv

Stanford and Rubedo researchers identify pain-dr

University of Copenhagen receives Longevity Scie

Polypharmacology meets machine learning as resea

Longevity biotech sector consolidates as cellula

Stately Bio founder explains how combining machi

Southern California initiative to focus on early

Controversial sporting event that encourages per

Tomorrow.

Epigenetic lineage tracing offers insight into h

Companies to collaborate on new Abu Dhabi drug d

Regeneron’s $256 million acquisition marks a p

San Francisco’s Frontier Tower transforms urba

Rejuvenate Biomed to study how metformin-galanta

New paper proposes tackling aging organ by organ

Natural endocrine therapy is designed to help re

Startup targets developmental biology’s ‘Alp

Exclusive investor event brings together scienti

Longevity field hails ‘landmark step’ as US